Top Markets
#1 MowCat MowCat +48.69%
#2 Bitway Bitway +30.40%
#3 Velvet Velvet +25.26%
#4 Fake World Assets Fake World Assets +24.64%
#5 aPriori aPriori +22.24%
#6 OVERTAKE OVERTAKE +17.93%
#7 Zerebro Zerebro +14.80%
#8 Biconomy Biconomy +13.31%
#9 Palladium Network Palladium Network +12.49%
#10 Derive Derive +12.34%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
株式のランク #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
株価
$0.6379482
最終同期: 2023-05-22
時価総額
$5.98M
変化（1日）
-0.44%
変化（1年）
0.00%
国
FR
取引 Nicox S.A. (COX)

カテゴリー

Healthcare
Nicox S.A.（COX）のP/B比率
2026 時点のP/B比率 TTM: 0
Nicox S.A. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Nicox S.A. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE